Genomic Profiles of Chinese Myeloid Malignancies with Clinical Correlates

Targeted next-generation sequencing data from 184 samples across 174 Chinese patients diagnosed with acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia. The dataset, created by Pengjun Liao and last updated in April 2026, contains mutation profiles and their associations with clinical features, disease progression, and prognosis.

Use Cases

• Identify frequent gene mutations (e.g., FLT3, NPM1, TP53) in specific myeloid malignancy subtypes based on the described mutation profiles.
• Analyze associations between genetic alterations (mutations and SNPs) and clinical outcomes like prognosis and disease progression based on the study's findings.
• Compare mutational landscapes between newly diagnosed and relapsed AML cases based on the reported differences in WT1 mutation incidence.
• Investigate prognostic indicators such as specific SNPs in FAT1, PDGFRA, SETBP1, and KMT2C for AML based on the results summary.

Strengths

• Data is derived from a targeted 110-gene panel applied to 184 samples, providing focused genomic coverage.
• Includes clinical correlates, associating mutations with features, progression, and prognosis for three myeloid malignancy types.
• Specifically focuses on a Chinese patient cohort (174 patients), addressing a noted data gap for this population.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for certain analytical tasks.
• The study's multivariate analysis found no independent prognostic factors, suggesting complex variable interactions.

Provenance

Source

figshare

Collection Method

Targeted next-generation sequencing using a 110-gene panel on patient samples.

Time Range

Study period not specified in input; data reflects a specific research cohort.

Freshness

Last updated 2026-04-30 13:22:52; freshness should be verified.

Geography

China (patient population)